Huge news in APOL1 nephropathy - ten tweets to fill you in here:
This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…
This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
Huge news in APOL1 nephropathy - ten tweets to fill you in here:
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) May 12, 2023
✳️10 tweets #NephJC catch-up ✳️
On 4/25-26, we discussed the phase II study examining inaxaplin treatment, a small molecule inhibitor, in APOL1 nephropathy. This is the first drug specifically targeting this disease.
Join us here for the recap! pic.twitter.com/LApAHkYn10